Evidence map›Paper›PMID 35201948›Full record

ArticleAutophagy2022

Susceptibility to autophagy inhibition is enhanced by dual IGF1R and MAPK/ERK inhibition in pancreatic cancer.

Clint A Stalnecker, Michael F Coleman, Kirsten L Bryant

Open access · bronzeAbstract readComment
In one paragraph

Article in Autophagy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
3.6field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. SERPINH1 and CTSZ are Key Markers of Glioma Angiogenesis.Journal of molecular neuroscience : MN · 2025
    Article
  6. Article
  7. Article
  8. The role of autophagy in pancreatic diseases.Frontiers in pharmacology · 2024
    Review
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Clint A StalneckerLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Michael F ColemanDepartment of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Kirsten L BryantLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0003-4026-0942
University of North Carolina at Chapel Hill · US

Funding

Integrated Training in Cancer Model SystemsT32CA009156 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DER, CHANNING J. · 1985 to 2020
$19.7M
Washington University SPORE in Pancreatic CancerP50CA196510 · NCI · WASHINGTON UNIVERSITY · PI HAWKINS, WILLIAM G · 2016 to 2020
$10.9M
Mechanistic dissection and inhibitor targeting of autophagy in RAS driven cancersR37CA251877 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BRYANT, KIRSTEN L · 2020 to 2025
$2.5M
Defining the contributions of WT RAS in RAS-mutant lung cancerF32CA232529 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI STALNECKER, CLINT A · 2018 to 2021
$193k
NCI NIH HHS F32 CA232529NCI NIH HHS P50 CA196510NCI NIH HHS R37 CA251877NCI NIH HHS T32 CA009156
6 · The paper itself

Abstract

Macroautophagy/autophagy is upregulated in pancreatic ductal adenocarcinoma (PDAC) and PDAC growth is reliant on autophagy. However, autophagy inhibitors as monotherapy have shown limited clinical efficacy. To identify targets that sensitize PDAC cells to autophagy inhibition, we performed a CRISPR-Cas9 genetic loss-of-function screen in cells treated with the lysosomal inhibitor chloroquine (CQ) and identified IGF1R as a sensitizer. IGF1R inhibition increases autophagic flux and sensitivity to CQ-mediated growth suppression both

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsAutophagyCell Line, TumorChloroquineHumansReceptor, IGF Type 1ChloroquineIGF1R protein, humanReceptor, IGF Type 1AutophagyIGF1RMAPK/ERKpancreatic cancertargeted therapies

Identifiers

PMID35201948
PMCPMC9298440
OpenAlexW4213434782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.